Loading...
Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
Barlesi, F Drilon, A De Braud, F Cho, BC Ahn, MJ Siena, S Krebs, Matthew G Lin, CC John, T Tan, DSW
Barlesi, F
Drilon, A
De Braud, F
Cho, BC
Ahn, MJ
Siena, S
Krebs, Matthew G
Lin, CC
John, T
Tan, DSW
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 84.58 KB
Keywords
Type
Meetings and Proceedings
Citation
Barlesi F, Drilon A, Braud FD, Cho BC, Ahn MJ, Siena S, et al. 109O Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2. Ann Oncol. 2019;30(Supplement_2).